33
Participants
Start Date
April 11, 2024
Primary Completion Date
February 14, 2025
Study Completion Date
February 14, 2025
Mucogyne Ovule
At inclusion visit (V0), the Investigator will ask the subject to use MUCOGYNE® Ovule 2 times a week until symptoms improve during 5 weeks (D35± 3) preferably at bedtime
Dr Raïssa APERANO-MAS's medical office, Rennes
Dr Ramez GHADRI's medical office, Orléans
JEAN Christian's medical office, Nogent-sur-Marne
Lead Sponsor
Voisin Consulting Life Science (VCLS)
UNKNOWN
Biocodex
INDUSTRY